| Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy S Spranger, D Dai, B Horton, TF Gajewski Cancer cell 31 (5), 711-723. e4, 2017 | 1216 | 2017 |
| Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly … S Spranger, HK Koblish, B Horton, PA Scherle, R Newton, TF Gajewski Journal for immunotherapy of cancer 2, 1-14, 2014 | 618 | 2014 |
| Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment TF Gajewski, L Corrales, J Williams, B Horton, A Sivan, S Spranger Tumor immune microenvironment in cancer progression and cancer therapy, 19-31, 2017 | 268 | 2017 |
| The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment JB Williams, BL Horton, Y Zheng, Y Duan, JD Powell, TF Gajewski Journal of Experimental Medicine 214 (2), 381-400, 2017 | 204 | 2017 |
| Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity BL Horton, JB Williams, A Cabanov, S Spranger, TF Gajewski Cancer immunology research 6 (1), 14-24, 2018 | 155 | 2018 |
| Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer BL Horton, DM Morgan, N Momin, M Zagorulya, E Torres-Mejia, ... Science immunology 6 (64), eabi8800, 2021 | 88 | 2021 |
| Tissue site and the cancer immunity cycle BL Horton, TB Fessenden, S Spranger Trends in cancer 5 (10), 593-603, 2019 | 48 | 2019 |
| Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer M Zagorulya, L Yim, DM Morgan, A Edwards, E Torres-Mejia, N Momin, ... Immunity 56 (2), 386-405. e10, 2023 | 41 | 2023 |
| Formation of human neuroblastoma in mouse-human neural crest chimeras MA Cohen, S Zhang, S Sengupta, H Ma, GW Bell, B Horton, B Sharma, ... Cell Stem Cell 26 (4), 579-592. e6, 2020 | 38 | 2020 |
| A prime editor mouse to model a broad spectrum of somatic mutations in vivo ZA Ely, N Mathey-Andrews, S Naranjo, SI Gould, KL Mercer, GA Newby, ... Nature biotechnology 42 (3), 424-436, 2024 | 16 | 2024 |
| A tumor cell-intrinsic yin-yang determining immune evasion B Horton, S Spranger Immunity 49 (1), 11-13, 2018 | 14 | 2018 |
| Back from the dead: TIL apoptosis in cancer immune evasion BL Horton, TF Gajewski British Journal of Cancer 118 (3), 309-311, 2018 | 13 | 2018 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| CD36 — the Achilles’ heel of Treg cells BL Horton, S Spranger Nature Immunology 21 (3), 251-253, 2020 | 7 | 2020 |
| Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies KG Anderson, DA Braun, A Buqué, SB Gitto, JL Guerriero, B Horton, ... Journal for immunotherapy of cancer 11 (6), 2023 | 5 | 2023 |
| 1087 Addition of IL-2 overcomes lung tumor resistance to IL-12 by coordinating cytotoxic and regulatory T cell responses B Horton, M Zagorulya, N Momin, Y Agarwal, K Wittrup, S Spranger J Immunother Cancer 10 (Suppl 2), A1-A1603, 2022 | 3 | 2022 |
| Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy A Ziblat, BL Horton, EF Higgs, K Hatogai, A Martinez, JW Shapiro, ... Cell Reports 43 (5), 2024 | 2 | 2024 |
| Dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment T Gajewski, J Williams, B Horton US Patent 11,566,077, 2023 | 2 | 2023 |
| The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions BL Horton, S Spranger Emerging Topics in Life Sciences 1 (5), 447-456, 2017 | 2 | 2017 |
Stefani SprangerMassachusetts Institute of Technology在 mit.edu 的电子邮件经过验证
